Should Goldman be Part of Your Portfolio Ahead of Its Q4 Earnings?

Should Goldman be Part of Your Portfolio Ahead of Its Q4 Earnings?

The Goldman Sachs Group, Inc. GS is scheduled to release fourth-quarter 2024 earnings on Jan. 15 before the opening bell.

Goldman’s close peer JP Morgan JPM is slated to announce quarterly numbers on Jan. 15, whereas Morgan Stanley MS will come out with its performance details on Jan. 16. Stay up-to-date with all quarterly releases: See Zacks Earnings Calendar.

In the third quarter of 2024, Goldman’s results benefited from the strength in investment banking (IB) business. However, a rise in provisions and a weak capital position were concerning.

Goldman has an impressive earnings surprise history. The company’s earnings outpaced the Zacks Consensus Estimate in the trailing four quarters, with an average earnings surprise of 29.33%.

 

Zacks Investment Research

Image Source: Zacks Investment Research

 

Let us see how GS is expected to fare in terms of revenues and earnings this time.

The Zacks Consensus Estimate for fourth-quarter revenues is pegged at $12.13 billion, calling for a 7% rise from the year-ago quarter’s reported figure.

In the past seven days, the consensus estimate for quarterly earnings has been revised downward to $7.87 per share. However, the projection suggests a rally of 43.6% from the year-ago quarter’s reported figure.

 

Zacks Investment Research
Zacks Investment Research

Image Source: Zacks Investment Research

 

Market-Making Revenues: The fourth quarter saw strong client activities and market volatility. Client activities were driven by the prospect of a robust economic expansion, a slowdown in inflation and an easing of monetary policy. Additionally, volatility was high in equity markets and other asset classes, including commodities, bonds and foreign exchange. Therefore, Goldman’s market-making revenues are likely to have witnessed a rise in the quarter to be reported.

IB Fees: Global mergers and acquisitions (M&As) improved significantly in the fourth quarter of 2024, following a weak performance in 2023 and 2022. Deal value and volume increased in the quarter, owing to strong financial performance, robust U.S. economic growth, buoyant markets and interest rate reduction. The possibility of lowering regulatory monitoring on M&As by the incoming Trump administration encouraged deal-making activity. However, persisting geopolitical difficulties hampered progress.

Given market volatility, geopolitical concerns and global monetary easing, the IPO market has shown signals of cautious optimism. The strong performance of the equity market prompted a surge in follow-up equity issuances. Despite typically low volumes in December, bond issuance activity was decent due to positive economic conditions and corporate spreads at near-historic lows.

More From Author

Portfolio Rebalancing Flows Signal Volatility Ahead for Year-End Trading

What to Buy for a Macro Portfolio in 2025

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs - Mesoblast (NASDAQ:MESO), Sana Biotechnology (NASDAQ:SANA)

Top 2 Health Care Stocks That Are Ticking Portfolio Bombs – Mesoblast (NASDAQ:MESO), Sana Biotechnology (NASDAQ:SANA)

Leave a Reply

Your email address will not be published. Required fields are marked *